Protocol

Tui Na for Chronic Nonspecific Low Back Pain: Protocol for a Systematic Review and Meta-analysis

Juan Yang1, MD, PhD; Jeffrey S Brault2, MD; Mark A Jensen2, PT; Alexander Do1, MD; Qingyu Ma3, MD, PhD; Xuan Zhou3, MD, PhD; Longbin Shen4, MD; Canghuan Zhao4, MD; Kwok Chee Philip Cheong5, MD; Kejie He6, MD; Yu Guo1, MD, PhD; Zhuoming Chen4, MD, PhD; Shujie Tang6, MD, PhD; Yong Tang6, MD, PhD; Celia Ia Choo Tan7, MD; Jiaxu Chen8, MD, PhD; Brent A. Bauer1*, MD

1Division of General Internal Medicine, Mayo Clinic, Rochester, MN, United States
2Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, MN, United States
3Formula-pattern Research Center, School of Traditional Chinese Medicine, Jinan University, Guangzhou, China
4Department of Acupuncture, The First Affiliated Hospital of Jinan University, Guangzhou, China
5School of Physiotherapy and Exercise Science, Singapore General Hospital, Singapore, Singapore
6Department of Orthopedics, College of Chinese Medicine, Jinan University, Guangzhou, China
7Allied Health, SingHealth Group, Singapore, Singapore

*all authors contributed equally

Corresponding Author:
Brent A. Bauer, MD
Division of General Internal Medicine
Mayo Clinic
200 1st St SW
Rochester, MN, 55905
United States
Phone: 1 5072842511
Email: Bauer.Brent@mayo.edu

Abstract

Background: Chronic nonspecific low back pain (CNLBP) is one of the most common complex pain conditions, and it is strongly associated with high rates of disability. Even though several studies on Tui na for CNLBP have been reported, to our knowledge there has been no systematic review of the currently available publications.

Objective: This study aims to develop a protocol for a systematic review and meta-analysis that will evaluate the effectiveness and safety of Tui na therapy for patients with CNLBP.

Methods: An electronic literature search of PubMed, Embase, MEDLINE, Cochrane Library, Springer, Scopus, World Health Organization International Clinical Trials Registry Platform, Physiotherapy Evidence Database (PEDro), Clarivate Analytics, and Chinese biomedical databases (the China National Knowledge Infrastructure, Wan-fang database, Chinese Scientific Journals Database, and Chinese Biomedical Literature Databases) will be conducted. Studies will be screened by two reviewers independently based on titles and abstracts, followed by a full-text reading with eligibility criteria. Randomized controlled trials involving Tui na for patients with CNLBP will be reviewed. The primary outcomes of the study are improvement of pain, analgesic medication reduction, improvement of functional disability, and degree of satisfaction with the intervention. A secondary outcome is any adverse event of Tui na intervention. Methodological quality and risk of bias will be assessed with the Cochrane Collaboration Risk of Bias Tool. If studies are sufficient, a meta-analysis of the effectiveness will be performed. If possible, we will evaluate publication bias using funnel plots. If substantial heterogeneity between studies is present, and there are sufficient studies, subgroup analyses will be conducted to explain the study findings.

Results: The review database searches will be initiated in December 2020, with findings expected by January 2021.

Conclusions: This protocol will establish a framework of a high-quality literature synthesis on the impact of Tui na treatment in patients with CNLBP. The proposed review will determine whether Tui na is effective and safe for CNLBP patients.

Trial Registration: PROSPERO CRD42020166731; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=166731

International Registered Report Identifier (IRRID): PRR1-10.2196/20615

http://www.researchprotocols.org/2021/1/e20615/
The primary objective of this review is to identify the evidence of Tui na therapy for patients suffering from CNLBP. Protocol for a systematic review and meta-analysis on the question of whether Tui na is effective and safe for the treatment of patients with CNLBP [13,17]. In some countries, Tui na is not even included in the guidelines for the treatment of LBP [18]. Thus, due to nonstandard measurement, nonuniform outcomes, and other factors, these individual studies do not provide sufficient evidence for the impact of Tui na in patients with CNLBP [13,17]. In some countries, Tui na is not even included in the guidelines for the treatment of LBP [18]. Thus, the question of whether Tui na is effective and safe for the management of CNLBP is an important one. A review to help assess the efficacy and safety of Tui na in CNLBP management is therefore important and timely. This paper aims to provide a protocol for a systematic review and meta-analysis on the evidence of Tui na therapy for patients suffering from CNLBP. The primary objective of this review is to identify the effectiveness of Tui na treatment among people with CNLBP.

Methods

This protocol was developed to adhere to the PRISMA-P 2015 (Preferred Reporting Items for Systematic Review and Meta-Analysis for Protocols 2015) [19]. This study will be conducted in accordance with the PRISMA guidelines [20].

Study Selection Criteria

The PICOS (patient, intervention, comparison, outcome, and study design) framework will be used to inform the eligibility criteria of studies [21,22]. Studies will be excluded if they meet any of the following criteria: (1) duplicate studies; (2) nonrandomized controlled trials; (3) literature reviews; (4) case reports; (5) studies comparing different types of Tui na; and (6) animal experiments.

Types of Studies

Any randomized controlled trial (RCT) involving Tui na therapy in the treatment group for patients with CNLBP will be included in this study.

Participants

Adults (aged 18 years and older) who were diagnosed with chronic, nonspecific (with no diagnosable underlying pathology) LBP will be included in this study. There are no limits on race, gender, age, nationality, etc.

Intervention

All trials evaluating Tui na intervention will be included. Experimental intervention can be any type of Tui na or Tui na combined with other therapies.

Comparison

Different control interventions such as no-treatment control, placebo, and other currently used interventions (such as health education, behavior therapy, acupuncture, moxibustion, physical therapies, medications, and gentle touch) will be included.

Outcomes

Primary outcomes will include improvement of pain, reduction in analgesic medication, improvement of functional disability, and degree of satisfaction with the intervention. A secondary outcome will be any adverse events (AEs) associated with Tui na.

Search Strategy

An electronic literature search will be applied to the following databases: PubMed, Embase, MEDLINE, Cochrane Library, Springer, Scopus, World Health Organization International Clinical Trials Registry Platform, Physiotherapy Evidence Database (PEDro), Clarivate Analytics, and Chinese biomedical databases (the China National Knowledge Infrastructure,
Wan-fang database, Chinese Scientific Journals Database, and Chinese Biomedical Literature Databases), from database inception to December 2020, limited to English and Chinese language only. Peer-reviewed journal articles and reference lists of final included studies, as well as grey literature including conference proceedings, dissertations, and white papers, will be used to help identify all applicable studies for inclusion.

The comprehensive literature search will be designed and carried out by an experienced librarian at Mayo Clinic, Rochester campus, with input from the study’s principal investigator. Controlled vocabulary and keywords will be used to search for publications describing the effect and safety of Tui na on patients with CNLBP.

Study Selection

The results of the literature search, including the abstract and citation, will be imported into EndNote X9 (Thomson Reuters Clarivate Analytics), and duplicate studies will be removed prior to the literature screening. Two authors will screen titles and abstracts on inclusion criteria independently. Publications that are not relevant or do not meet the inclusion criteria will be removed. The whole selection process will be presented in the PRISMA flowchart of Figure 1. Any selection divergence will be resolved by the consensus between the two authors or by consulting the original corresponding author.

Figure 1. PRISMA diagram of identified studies.
Methodological Quality and Risk of Bias Appraisal

To ensure reliability, the risk of bias of each study included in our study will be assessed independently by two authors using the special assessment tool recommended by the Cochrane Collaboration [23], including selection, performance, attrition, detection, reporting, and other biases. An assessment disagreement between the two authors will be discussed between the two authors or by involving a third reviewer until a consensus is reached. Any discrepancies will be resolved through discussion or by involving a third reviewer.

Data Extraction

Important data associated with our study will be extracted from the included studies using a designed and piloted data collection Excel spreadsheet (Microsoft Corp) by two authors independently. Data will include characteristics of the studies including the first author, published year, sample size, population, and outcome measurement, and detailed information about the interventions such as observation group, control group, provider, frequency, efficacy, AEs, and follow-up.

Adverse Event Severity

The AE severity is evaluated with the Common Terminology Criteria for Adverse Events (CTCAE) [24]. The CTCAE Scale uses Grades 1 through 5 as follows: Grade 1 (mild AE), Grade 2 (moderate AE), Grade 3 (severe AE), Grade 4 (life-threatening or disabling AE), and grade 5 (death AE). Disagreements will be resolved by discussions. If necessary, the corresponding author will be contacted for clarification.

Assessment of Reporting Bias

Funnel plots will visually reveal the publication bias if the number of included trials for data analysis is sufficient (a minimum of 10 trials). Egger and Begg tests will be carried out to check the asymmetry of the funnel plot. A symmetric funnel plot represents a low risk of reporting bias, while a dissymmetric funnel plot represents a high risk.

Data Synthesis

Descriptive analysis or meta-analysis will be conducted according to the interventions, the measurements, and heterogeneity levels. Quantitative findings will be descriptively reported. Continuous variables are analyzed using mean difference and 95% CI, while dichotomous variables will be analyzed using odds ratio. If outcome measure scales are different, the standardized mean difference and 95% CI will be calculated. Study heterogeneity will be calculated within each pairwise comparison by $Q$ test and $I^2$ statistic; higher values indicate higher heterogeneity. $I^2\leq0\%$ indicates no heterogeneity; $I^2<25\%$ indicates low, $25\%<I^2<50\%$ indicates moderate, while $50\%<I^2<75\%$ indicates substantial, and $75\%<I^2<100\%$ indicates considerable heterogeneity [25]. If at least 2 included trials are sufficiently homogenous in terms of study design, comparator, and outcome measurement, a meta-analysis will be performed using a random-effects model. Review Manager software (RevMan 5.3) provided by the Cochrane Collaboration will be applied for the meta-analysis. If substantial heterogeneity between studies is present and there are sufficient RCTs, subgroup analyses will be performed to explain clinical heterogeneity effects on study intervention, pain intensity, and measurement tool.

Ethics and Dissemination

The proposed review will only synthesize previous publications. No research ethics committee review approval is required. Results from this study will be disseminated as a peer-reviewed journal article and presented in conferences.

Results

This protocol has been registered on PROSPERO (CRD42020166731) on April 28, 2020 [26]. The review database searches will be initiated in October 2020. The literature search strategy is presented in Figure 1. Study results will be submitted for publication in January 2021.

Discussion

By means of the proposed systematic review, we intend to assess the impact of Tui na in CNLBP. Tui na therapy is a very common, convenient, noninvasive, and relatively inexpensive therapy that has historically been used successfully to treat low back pain [11]. However, Tui na is still not included in the guidelines for the treatment of LBP in most countries, especially those using the mainly Western form of medicine, though other manual therapies are gaining acceptance (eg, chiropractic) [18]. In regard to CNLBP, the evidence is still unclear, preventing its successful adoption into the list of potential treatment options. Thus, the need for this proposed review is clear; to our knowledge, it will be the first to objectively synthesize the currently available publications and evaluate the effect and safety of Tui na for CNLBP patients.

Recognizing that missing data could introduce greater uncertainty and possible bias in estimating the effect of experimental treatment in our meta-analysis, two authors will independently screen, select, and evaluate the data. Any divergence for missing information or unclear information (eg, on study methods or results) will be resolved by consensus between the two authors or by consulting the original corresponding author.

Given the narrowness of our research question, it is possible that only a few RCTs could be included in the proposed systematic review. It is our hope that even should this occur, the research results can still be valuable as a summary of currently available evidence, which may provide some preliminary guidance to inform existing low back pain practice and future research. Finally, to broaden our data and to minimize publication bias, we will conduct the electronic search for studies in both Chinese and English. In the future, as new evidence is made available, the systematic review and meta-analysis is planned to be updated every 1 to 3 years.

This protocol intends to provide a framework of evidence on Tui na therapy for patients with CNLBP that can be used by health care providers worldwide. It is also intended to lay the foundation for future Tui na studies with greater attention.
focused on remediing deficits found in many of the current studies.

Acknowledgments
The authors thank Prof Tay Boon Keng, the leading Chairman, Medical Board, International, SingHealth, for his initial study proposal of Tui na treatment for low back pain. This work has been supported by The HEAD Foundation, Singapore. Their support is gratefully acknowledged.

Authors’ Contributions
BAB contributed to the study conceptualization, investigation, and funding acquisition. JY, ZC, ST, and YT curated the data. JY and AD analyzed the data. JY, XZ, and QM developed the study methodology. BAB, JC, and CICT contributed to project administration and supervision. JY, XZ, and LS contributed to software. JY, JSB, XZ, and QM wrote the original draft of the manuscript. BAB, JC, CICT, JSB, MAJ, CZ, and KCPC reviewed and edited the manuscript.

Conflicts of Interest
None declared.

References

Abbreviations
AE: adverse event
CAM: complementary and alternative medicine
CLBP: chronic low back pain
CNLBP: chronic nonspecific low back pain
CTCAE: Common Terminology Criteria for Adverse Events
PRISMA-P: Preferred Reporting Items for Systematic Review and Meta-Analysis for Protocols
RCT: randomized controlled trial

Edited by G Eysenbach; submitted 24.05.20; peer-reviewed by AR Safarpour, J Li; comments to author 07.07.20; revised version received 06.09.20; accepted 15.12.20; published 27.01.21

Please cite as:
URL: http://www.researchprotocols.org/2021/1/e20615/
doi: 10.2196/20615
PMID: 33502327